New hope for tough blood cancers: LP-118 trial launches

NCT ID NCT04771572

Recruiting now Disease control Sponsor: Newave Pharmaceutical Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease. Participants take the drug once daily, and researchers monitor side effects and how the body processes the medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia chronic myelomonocytic leukemia hematopoietic and lymphoid system neoplasm myelodysplastic syndrome myelodysplastic/myeloproliferative disease myelodysplastic/myeloproliferative neoplasm myelofibrosis non-Hodgkin lymphoma plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma primary myelofibrosis Recurrence Richter transformation T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOCYTIC LEUKEMIA ACUTE MYELOID LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA-2 MULTIPLE MYELOMA MYELODYSPLASTIC NEOPLASM IN BLAST PHASE MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM MYELOFIBROSIS MYEODYSPLASTIC SYNDROME NON-HODGKIN LYMPHOMA RICHTER TRANSFORMATION SMALL LYMPHOCYTIC LYMPHOMA T-CELL PROLYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
University of Cincinnati
RECRUITING

Cincinnati, Ohio, 45229, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.